• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Video

Dermatology Times Chief Medical Editor Weighs in On Black Box Warning for JAK Inhibitors

Author(s):

Morgan Petronelli

In this exclusive video interview, Zoe Diana Draelos, MD, Dermatology Times chief medical editor, weighs in on the recent Black Box Warning issued by the FDA to certain JAK inhibitors.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!
Related Videos
Related Content
FDA News and Decisions: Midyear Updates
July 11th 2025

FDA News and Decisions: Midyear Updates

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics
September 23rd 2021

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

Jasper Investigates Drug Lot Issue in CSU Study
July 8th 2025

Jasper Investigates Drug Lot Issue in CSU Study

The Cutaneous Connection
September 2nd 2021

The Cutaneous Connection: Episode 30- Impact of the JAK Inhibitor Approval Delays

New Research Highlights Zabalafin Hydrogel's Novel Multitargeted Approach to AD Treatment
July 2nd 2025

New Research Highlights Zabalafin Hydrogel's Novel Multitargeted Approach to AD Treatment

FDA Grants Rare Pediatric Disease Designation to QRX003 for Netherton Syndrome
June 27th 2025

FDA Grants Rare Pediatric Disease Designation to QRX003 for Netherton Syndrome

© 2025 MJH Life Sciences

All rights reserved.